Nasdaq

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for ...
ascopubs.org

Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC ...

New HSP90 selective inhibitors as therapeutic agents for prostate and bladder cancer. Abiraterone acetate in metastatic castration-resistant prostate cancer post-docetaxel: A “real-life” retrospective ...
Benzinga.com

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck MRK, known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been ...